The Effect of Treatment of Vitamin D Deficiency on the Level of P-Selectin and hs-CRP in Patients With Thromboembolism: A Pilot Randomized Clinical Trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Despite the known role of vitamin D deficiency in development of thrombosis, no studies have evaluated the impact of treating of vitamin D deficiency on the markers of thrombosis.

A pilot randomized clinical trial was done on 40 vitamin D-deficient patients with deep vein thrombosis (DVT) or pulmonary embolism (PE).

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized and pilot study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

It is described as a pilot, a small early test of whether a larger Vitamin D, K2, Magnesium and Zinc study would be practical.

Then, P-selectin and hs-CRP were measured at baseline and 1 and 3 months after the intervention.

What Was Measured

Despite the known role of vitamin D deficiency in development of thrombosis, no studies have evaluated the impact of treating of vitamin D deficiency on the markers of thrombosis.

PubMed files the paper under topics including Biomarkers, C-Reactive Protein, P-Selectin, Pilot Projects, Thromboembolism, Vitamin D and Vitamin D Deficiency.

The authors tagged it with the keywords hs-CRP.

What This Means in Plain Language

The paper is a randomized and pilot study of Vitamin D, K2, Magnesium and Zinc.

The publication is from 2017 (Journal of clinical pharmacology), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.